ArticleInflammopharmacology2026
Metformin alleviates presbycusis by activating the SIRT1/PINK1/GPX4 pathway in vitro and in vivo.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic Timing at Mitochondrial Redox-Autophagy-Mitophagy Checkpoints in Age-Related Hearing Loss.Molecular neurobiology · 2026Review
- Role of YAP/TAZ Mechanobiological Signaling in Osteoporosis and Osteoarthritis.Calcified tissue international · 2026Review
- Gut-Metabolome-Proteome Interactions in Age-Related Hearing Loss: Insights from Fecal Microbiota Transplantation and Multi-Omics Analyses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPresbycusis is a neurodegenerative disease associated with chronic inflammation. Metformin is an anti-inflammatory agent used to treat diabetes. However, its efficacy in delaying presbycusis has not been established.
aimThe study aimed to investigate the protective effects of metformin against presbycusis and elucidate its mechanistic role in modulating the SIRT1/PINK1/GPX4 signaling pathway in vitro and in vivo. MATERIALS AND
methodsThe target genes of presbycusis were identified using bioinformatics. The HEI-OC1 cells were subsequently induced with D-galactose (D-gal) and co-treated with metformin in vitro. Their viability, mitochondrial function, and molecular markers were subsequently monitored. Meanwhile, C57BL/6J mice were injected with metformin, and their auditory brainstem response (ABR) thresholds were assessed by ABR test. Animal histopathological examination, immunofluorescence staining, and western blotting were used to assess the protective effects of metformin against presbycusis in mice.
resultsMetformin increased the viability of senescent auditory cells, enhanced mitochondrial function by reducing reactive oxygen species production, and inhibited ferroptosis in vitro. It also improved the auditory function of C57BL/6J mice, reduced their cochlear concentrations of Fe
conclusionMetformin activates the SIRT1/PINK1/GPX4 signaling pathway, and it may be effective for treating presbycusis.
Indexed as
Identifiers
41269477What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.